التفاصيل البيبلوغرافية
| العنوان: |
Patent Issued for Viral vectors for cancer therapy (USPTO 11918660). |
| المصدر: |
Cancer Vaccine Week; 2024, p188-188, 1p |
| مصطلحات موضوعية: |
GENETIC vectors, HUMAN herpesvirus 1, CANCER treatment, HUMAN herpesvirus 2 |
| مستخلص: |
Krystal Biotech Inc. has been issued a patent for viral vectors for cancer therapy. The patent describes recombinant herpes virus genomes that encode immunomodulatory polypeptides for use in treating cancer. The recombinant herpes virus genomes can be replication competent or replication defective and may contain inactivating mutations in certain herpes simplex virus genes. The patent also includes claims for pharmaceutical compositions comprising the recombinant herpes simplex virus genomes and polynucleotides encoding interleukin-2 and interleukin-12 polypeptides. This research aims to develop more effective cancer treatment options. [Extracted from the article] |
|
Copyright of Cancer Vaccine Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
